ArticleNeuro-oncology practice2023
Patterns of care and survival of Chinese glioblastoma patients in the temozolomide era: a Hong Kong population-level analysis over a 14-year period.
Article in Neuro-oncology practice, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 16 citations in OpenAlex.
- Neuromotor modules revealed by direct electrical stimulation of the human primary motor cortex.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Health-related quality-of-life of WHO grade 4 astrocytoma patients receiving alternating electrical field therapy: a prospective real-world multi-centre study.Journal of neuro-oncology · 2026Article
- Mapping glioblastoma's isoform diversity using long-read single-cell analysis.Nature communications · 2026Article
- VAL-083 is effective in patients with newly-diagnosed MGMT-unmethylated glioblastoma: report of phase II study.Discover oncology · 2025Article
- Spinal Metastasis from Supratentorial Glioblastoma: A Registry-Based Case Series and a Review of the Literature.Cancers · 2025Article
- Impact of alternating electric fields therapy for newly diagnosed WHO grade 4 astrocytoma on patient survival: a real-world propensity-score adjusted prospective multicenter study.Journal of neuro-oncology · 2025Article
- Epidemiology of glioblastoma in Pakistan: a secondary analysis of the Pakistan Brain Tumor Epidemiology Study (PBTES).Journal of neuro-oncology · 2025Article
- Patterns of care and survival in patients with multifocal glioblastoma: A Danish cohort study.Neuro-oncology practice · 2024Article
- Survival of Patients with Primary Brain Tumor: A Data Analysis of 10 Years.Current pharmaceutical design · 2024Article
- High costs, low quality of life, reduced survival, and room for improving treatment: an analysis of burden and unmet needs in glioma.Frontiers in oncology · 2024Review
- The benefit of complete resection of contrast enhancing tumor in glioblastoma patients: A population-based study.Neuro-oncology practice · 2023Article
- Epidemiological characteristics and genetic alterations in adult diffuse glioma in East Asian populations.Cancer biology & medicine · 2022Review
- Outcomes of H3K27M-altered diffuse midline glioma adult Chinese patients and real-world experience with German-sourced ONC201 targeted therapy: A multi-center study in Hong Kong.Neuro-oncology advancesArticle
- The impact of timing of temozolomide chemoradiotherapy for newly diagnosed glioblastoma on patient overall survival: A multicenter retrospective study.Neuro-oncology advancesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors at 9 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The aim of this study is to address the paucity of epidemiological data regarding the characteristics, treatment patterns and survival outcomes of Chinese glioblastoma patients. Methods: This was a population-level study of Hong Kong adult ( Results: One thousand and ten patients with a median follow-up of 10.0 months were reviewed. The ASIR of glioblastoma was 1.0 per 100 000 population with no significant change during the study period. The mean age was 57 Conclusions: The incidence of glioblastoma in the Chinese general population is low. We charted the development of neuro-oncological care of glioblastoma patients in Hong Kong during the temozolomide era. Although there was an increased adoption of temozolomide chemoradiotherapy, a corresponding improvement in survival was not observed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.